RESEARCH PEPTIDE FUNDAMENTALS / COLOPHON
About Best Peptide
An independent literature desk built around one discipline: say what the evidence actually supports, and say plainly when it doesn't support much yet.
What Best Peptide is
Best Peptide is an independent editorial reference desk covering five research peptides that are frequently discussed together but sit at very different points on the evidence ladder: CJC-1295, ipamorelin, KPV, retatrutide, and semaglutide, with semaglutide as the lead compound on the strength of its trial record. The desk exists because research-peptide marketing routinely treats 'published research exists' as equivalent to 'this works and is safe,' when a single eleven-person pharmacokinetic study and a 17,000-participant randomized outcome trial are not remotely the same kind of evidence, even though both technically qualify as published research.
The organizing idea is to grade evidence honestly across categories that do not normally get compared side by side: a growth-hormone-releasing-hormone analog, a ghrelin-receptor secretagogue, an anti-inflammatory tripeptide, an investigational metabolic triple-agonist, and one fully approved metabolic drug. Reading them together makes the differences in evidence maturity harder to miss than reading any one compound's marketing in isolation.
How it is compiled
Three habits govern what appears on this site. First, every factual claim is tied to a specific citation on the references page — peer-reviewed journal articles and clinical-trial publications, with DOIs and PubMed links, and each compound page distinguishes primary research from review-level synthesis. Second, findings are reported in the species and population actually studied: a rat pharmacology result is labeled as a rat result; an eleven-person study is labeled as small; a Phase 2 trial is labeled as Phase 2, not silently upgraded to proven. Third, where the published record is thin or entirely absent in humans — as with KPV — this desk says so directly rather than filling the gap with confident-sounding mechanism talk borrowed from animal data.
Community-reported experiences are included where they exist, because they are genuinely part of how these compounds are discussed, but every such paragraph is explicitly labeled as anecdotal and unverified, and none of it is presented as though it came from a controlled trial.
What it is not
Best Peptide is not a pharmacy, clinic, telehealth service, or vendor of any kind. It does not sell, source, or broker any compound, and it has no affiliate or referral relationship with any research-chemical supplier, pharmaceutical company, or telehealth provider. It does not diagnose, prescribe, or recommend a dose, schedule, or route of administration for any person, for any of the five compounds covered here.
Semaglutide is an approved prescription medicine available only through licensed medical providers. Retatrutide is investigational and not legally available outside registered clinical trials. CJC-1295, ipamorelin, and KPV are, by regulatory status, research chemicals with no approved human indication anywhere; nothing on this site should be read as encouragement to obtain or use any of them outside a legitimate research or clinical context. Readers seeking medical guidance should consult a licensed clinician. Editorial correspondence on citations, corrections, or newly published research can be directed to the contact page.